Prevalence and determinants of anemia in the immediate postkidney transplant period

Transplant International

Volumn 24, Issue 12, 2011, Pages 1208-1215

  Poesen, Ruben ^a   Bammens, Bert ^a   Claes, Kathleen ^a   Kuypers, Dirk ^a   Vanrenterghem, Yves ^a   Monbaliu, Diethard ^a   Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

anemia; erythropoiesis stimulating agent; ferritin; iron; post transplant anemia; renal transplantation

Indexed keywords

CYCLOSPORIN; FERRITIN; HEMOGLOBIN; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TACROLIMUS;

ADULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION; HOSPITALIZATION; HUMAN; IRON METABOLISM; IRON THERAPY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POST TRANSPLANT ANEMIA; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; AGED; ANEMIA; BELGIUM; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREVALENCE; RISK FACTORS;

EID: 80755153167     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01340.x     Document Type: Article

References (38)

1. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3: 835.
2. Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81: 1112.
3. Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, Andreon KA,. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429.
4. Al-Khoury S, Shah N, Afzali B, Covic A, Taylor J, Goldsmith D,. Post-transplantation anaemia in adult and paediatric renal allograft recipients-Guy's Hospital experience. Nephrol Dial Transplant 2006; 21: 1974.
5. Shibagaki Y, Shetty A,. Anaemia is common after kidney transplantation, especially among African Americans. Nephrol Dial Transplant 2004; 19: 2368.
6. Lorenz M, Kletzmayr J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G,. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 2002; 13: 794.
7. Imoagene-Oyedeji AE, Rosas SE, Doyle AM, Goral S, Bloom RD,. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006; 17: 3240.
8. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A,. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004; 15: 1347.
9. Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003; 3: 1426.
10. Turkowski-Duhem A, Kamar N, Cointault O, et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 2005; 80: 903.
11. Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D,. Anemia after renal transplantation. Am J Kidney Dis 2006; 48: 519.
12. Winkelmayer WC, Chandraker A,. Posttransplantation anemia: management and rationale. Clin J Am Soc Nephrol 2008; 3 (Suppl. 2): S49.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
14. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1.
15. Zheng S, Coyne DW, Joist H, et al. Iron deficiency anemia and iron losses after renal transplantation. Transpl Int 2009; 22: 434.
16. Sun CH, Ward HJ, Paul WL, Koyle MA, Yanagawa N, Lee DB,. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989; 321: 151.
17. Ferrucci L, Guralnik JM, Bandinelli S, et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 2007; 136: 849.
18. Eckardt KU, Mollmann M, Neumann R, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989; 84: 1160.
19. Bernhardt WM, Wiesener MS, Weidemann A, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170: 830.
20. Mathew TH,. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
21. Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
22. Friend P, Russ G, Oberbauer R, et al. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int 2007; 20: 754.
23. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE,. Posttransplant erythrocytosis. Kidney Int 2003; 63: 1187.
24. Stigant CE, Cohen J, Vivera M, Zaltzman JS,. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58.
25. Scornik JC, Schold JD, Bucci M, Meier-Kriesche HU,. Effects of blood transfusions given after renal transplantation. Transplantation 2009; 87: 1381.
26. Luban NL,. Transfusion safety: where are we today? Ann N Y Acad Sci 2005; 1054: 325.
27. Mason DP, Little SG, Nowicki ER, et al. Temporal pattern of transfusion and its relation to rejection after lung transplantation. J. Heart Lung Transplant 2009; 28: 558.
28. Heinze G, Kainz A, Horl WH, Oberbauer R,. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009; 339: b4018.
29. Singh AK, Szcech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085.
30. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071.
31. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019.
32. Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209.
33. Johannes T, Mik EG, Nohe B, Unertl KE, Ince C,. Acute decrease in renal microvascular PO2 during acute normovolemic hemodilution. Am J Physiol Renal Physiol 2007; 292: F796.
34. Heyman SN, Khamaisi M, Rosen S, Rosenberger C,. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008; 28: 998.
35. Okada T, Sawada T, Kubota K,. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation 2007; 84: 504.
36. Imamura R, Moriyama T, Isaka Y, et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007; 83: 1371.
37. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N,. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367.
38. Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant 2010; 10: 1695.